

Aimmune Therapeutics, Inc.

Form 4

August 11, 2015

**FORM 4****UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

Check this box  
if no longer  
subject to  
Section 16.  
Form 4 or  
Form 5  
obligations  
may continue.  
See Instruction  
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF  
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

## OMB APPROVAL

OMB  
Number: 3235-0287  
Expires: January 31,  
2005  
Estimated average  
burden hours per  
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**ENRIGHT PATRICK G**

(Last) (First) (Middle)

**C/O LONGITUDE CAPITAL  
PARTNERS II, LLC, 800 EL  
CAMINO REAL, SUITE 220**

(Street)

**MENLO PARK, CA 94025**

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading  
Symbol

**Aimmune Therapeutics, Inc. [AIMT]**

3. Date of Earliest Transaction  
(Month/Day/Year)

**08/11/2015**

4. If Amendment, Date Original  
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to  
Issuer

(Check all applicable)

☒ Director ☒ 10% Owner  
☐ Officer (give title below) ☐ Other (specify below)

6. Individual or Joint/Group Filing(Check  
Applicable Line)  
☒ Form filed by One Reporting Person  
☐ Form filed by More than One Reporting  
Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock, \$0.0001 par value	08/11/2015		C	3,873,530	A 11 3,873,530	I	By: Longitude Venture Partners II, L.P. (2)
Common Stock, \$0.0001 par value	08/11/2015		C	3,248,600	A 11 7,122,130	I	By: Longitude Venture Partners II, L.P. (2)
	08/11/2015		P(3)	312,500	A \$ 16 7,434,630	I	

# Edgar Filing: Aimmune Therapeutics, Inc. - Form 4

Common  
Stock,  
\$0.0001  
par value

By:  
Longitude  
Venture  
Partners II,  
L.P. <sup>(2)</sup>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount Number Shares
Series A Convertible Preferred Stock	<u>(1)</u>	08/11/2015		C		3,873,530		<u>(1)</u>	<u>(4)</u>	Common Stock	3,873,
Series B Convertible Preferred Stock	<u>(1)</u>	08/11/2015		C		3,248,600		<u>(1)</u>	<u>(4)</u>	Common Stock	3,248,

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
ENRIGHT PATRICK G C/O LONGITUDE CAPITAL PARTNERS II, LLC 800 EL CAMINO REAL, SUITE 220 MENLO PARK, CA 94025	X	X		

## Signatures

/s/ Warren L. DeSouza, as Attorney-in-Fact for Patrick G.  
Enright

08/11/2015

           \*\*Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) The Series A Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Issuer's Common Stock on a 1 for 1 basis immediately prior to the closing of Issuer's initial public offering.

The shares are held by Longitude Venture Partners II, L.P. ("Longitude Venture II"). Longitude Capital Partners II, LLC ("Longitude Capital II") is the general partner of Longitude Venture II and may be deemed to have sole voting, investment and dispositive power over

- (2) the shares held by Longitude Venture II. Patrick G. Enright is a managing member of Longitude Capital II and in his capacity as such may be deemed to exercise shared voting and investment power over the shares held by Longitude Venture II. Mr. Enright disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

- (3) Longitude Capital II purchased an additional 312,500 shares of Issuer's common stock in connection with the initial public offering at the offering price of \$16.00 per share.

- (4) The Series A Convertible Preferred Stock and Series B Preferred Convertible Stock have no expiration date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.